We are a clinical stage pharmaceutical company, developing complex active pharmaceutical ingredients (APIs), formulations, and life cycle management (LCM) products such as Depot long acting injections. The company’s lead product Glatiramer Acetate (GA, Copaxone®) Depot, a once-monthly IM injection of 40mg GA for the treatment of multiple sclerosis (a $20 billion market). Mapi is engaged in the development of Pregabalin ER for the treatment of neuropathic pain and epilepsy, Paliperidone Palmitate and Buspirone ER for the treatment of schizophrenia and other long acting Depot injectable treatments. Mapi Pharma Ltd. was founded in 2008 and is located in Ness Ziona, Israel and has GMP approved API and FDF facilities.